CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma.
Human high-grade glioma is heterogeneous in nature based on pathological and genetic profiling. Various tumour suppressor gene alterations are considered as prognostic markers in high-grade glioma. Gene expression of CDKN2A (p16) is used in various cancers as a prognostic biomarker along with methylation and deletion status of this gene. Expression levels of p16 mRNA were not studied as a biomarker in gliomas before. In this study, we have performed mRNA quantification analysis on 48 high-grade glioma tissues and checked for a possible prognostic role. The decreased expression of p16 mRNA in majority of the tumour tissues (57.1 %) was observed when compared to control tissues (P = 0.02). mRNA expression level was correlated with clinical variables also. p16 deletion status and BMI1 mRNA expression were also considered for comparison. p16 mRNA was negatively correlated with the BMI1 mRNA (P = <0.0001) but not with p16 deletion. p16 mRNA expression, midline shift in MRI and tumour type were able to predict patient survival in overall survival (OS) and progression-free survival (PFS). p16 mRNA could independently predict prognosis of OS (P = 0.0146) and PFS (P = 0.0305) in multivariate analysis. We have shown that p16 mRNA expression can act as an independent prognostic biomarker in high-grade glioma.
Department of Human Genetics, National Institute of Mental Health and Neuro Sciences, Bangalore, India, 560029.
M K
MK
Sibin
Department of Neurosurgery, National Institute of Mental Health and Neuro Sciences, Bangalore, India, 560029.
Dhananjaya I
DI
Bhat
Department of Neurosurgery, National Institute of Mental Health and Neuro Sciences, Bangalore, India, 560029.
K V L
KV
Narasingarao
Department of Human Genetics, National Institute of Mental Health and Neuro Sciences, Bangalore, India, 560029.
Ch
Ch
Lavanya
Department of Human Genetics, National Institute of Mental Health and Neuro Sciences, Bangalore, India, 560029. drchetangk@gmail.com.
G K
GK
Chetan
D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000235:genetics*; D001932:Brain Neoplasms / Q000235:genetics* / Q000473:pathology; D002648:Child; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics*; D019175:DNA Methylation / Q000235:genetics; D018572:Disease-Free Survival; D005260:Female; D005910:Glioma / Q000235:genetics* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D063150:Polycomb Repressive Complex 1 / Q000235:genetics; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics*; D055815:Young Adult
C069077:BMI1 protein, human; D014408:Biomarkers, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16; D012333:RNA, Messenger; D063150:Polycomb Repressive Complex 1
Decreased expression; Gene expression; Glioma; p16